Cite
HARVARD Citation
Moreno, V. et al. (n.d.). 794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors. Journal for immunotherapy of cancer. pp. A474-A475. [Online].